Synopsis
Synopsis
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (-)-menthol
2. 2216-51-5
3. Levomenthol
4. L-(-)-menthol
5. Menthomenthol
6. Menthacamphor
7. Peppermint Camphor
8. (1r,2s,5r)-2-isopropyl-5-methylcyclohexanol
9. U.s.p. Menthol
10. Levomentholum
11. Racementhol
12. (1r,2s,5r)-(-)-menthol
13. (-)-menthyl Alcohol
14. (-)-(1r,3r,4s)-menthol
15. Menthol Racemic
16. Hexahydrothymol
17. (1r)-(-)-menthol
18. D,l-menthol
19. (r)-(-)-menthol
20. 89-78-1
21. D-(-)-menthol
22. Menthol, Dl-
23. I-menthol
24. Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r,2s,5r)-
25. P-menthan-3-ol
26. (-)-trans-p-menthan-cis-ol
27. Rac-menthol
28. 1-menthol
29. (l)-menthol
30. Menthol(-)
31. (1r,2s,5r)-5-methyl-2-(propan-2-yl)cyclohexan-1-ol
32. Menthol, (1r,3r,4s)-(-)-
33. (1r,3r,4s)-(-)-menthol
34. Nci-c50000
35. Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r,2s,5r)-rel-
36. 1r-menthol
37. Nsc 62788
38. Racemic Menthol
39. Water-soluble Menthol
40. (1r,2s,5r)-menthol
41. 5-methyl-2-(1-methylethyl)cyclohexanol
42. (1r,2s,5r)-2-isopropyl-5-methylcyclohexan-1-ol
43. (1r,2s,5r)-rel-2-isopropyl-5-methylcyclohexanol
44. Bz1r15mtk7
45. (1r,2s,5r)-5-methyl-2-(1-methylethyl)cyclohexanol
46. (1r-(1-alpha,2-beta,5-alpha))-5-methyl-2-(1-methylethyl)cyclohexanol
47. (1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexan-1-ol
48. Menthol Crystals
49. Chembl470670
50. Ys08xha860
51. Chebi:15409
52. Menthol Natural
53. Nsc2603
54. (1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanol
55. (1r,2s,5s)-2-isopropyl-5-methyl-cyclohexanol
56. Headache Crystals
57. Nsc-2603
58. Fema No. 2665
59. Nsc-62788
60. Menthol (van)
61. Racementholum
62. Thymomenthol
63. Menthol, Cis-1,3,trans-1,4-
64. Racementol
65. L-menthol (natural)
66. Nsc 2603
67. (+-)-menthol
68. Dsstox_cid_2180
69. Menthol Racemique
70. Levomenthol [inn:ban]
71. Racementhol [inn:ban]
72. Cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1r-(1.alpha.,2.beta.,5.alpha.)]-
73. Dsstox_rid_75798
74. Dsstox_rid_76516
75. Dsstox_gsid_20805
76. Dsstox_gsid_22180
77. Menthol Natural, Brazilian
78. Menthol, L-
79. Racementol [inn-spanish]
80. Rel-(1r,2s,5r)-2-isopropyl-5-methylcyclohexanol
81. Levomentholum [inn-latin]
82. Menthol Racemique [french]
83. Racementholum [inn-latin]
84. Tra-kill Tracheal Mite Killer
85. (1alpha,2beta,5alpha)-5-methyl-2(1-methylethyl)cyclohexanol
86. Mfcd00062979
87. Cas-89-78-1
88. Ccris 375
89. Cas-2216-51-5
90. L-menthol (tn)
91. Ccris 3728
92. Ccris 4666
93. Hsdb 5662
94. Sr-05000001936
95. (-)-p-menthan-3-ol
96. Einecs 201-939-0
97. Einecs 218-690-9
98. Einecs 239-388-3
99. Unii-bz1r15mtk7
100. Brn 1902288
101. Brn 3194263
102. Levomentol
103. Unii-ys08xha860
104. (+-)-(1r*,3r*,4s*)-menthol
105. Ss-bisabolol
106. Ai3-52408
107. Laevo-menthol
108. Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.beta.,5.alpha.)-
109. Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r-(1alpha,2beta,5alpha))-
110. Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r-(1.alpha.,2.beta.,5.alpha.))-
111. L-menthol Natural
112. 1 -menthol
113. Ncgc00159382-02
114. Dextro,laevo-menthol
115. Meggezone
116. Menthol Crystals Usp
117. L-mentholum
118. L-menthol (jp17)
119. Spectrum_000305
120. Levomenthol [ii]
121. Menthol [mi]
122. 5-methyl-2-(1-methylethyl)cyclohexanol, (1alpha,2beta,5alpha)-
123. L-menthol [jan]
124. Menthol, (+/-)-
125. Spectrum2_000855
126. Spectrum3_001561
127. Spectrum5_001060
128. Levomenthol [inn]
129. Racementhol [inn]
130. M0545
131. Dl-menthol [jan]
132. Menthol [who-dd]
133. Menthol,3,trans-1,4-
134. Levomenthol [hsdb]
135. Racementhol [hsdb]
136. Ec 201-939-0
137. Ec 218-690-9
138. Schembl4613
139. Bspbio_003062
140. Kbioss_000785
141. Levomenthol [who-dd]
142. 2-06-00-00052 (beilstein Handbook Reference)
143. 4-06-00-00151 (beilstein Handbook Reference)
144. Mls002207256
145. Divk1c_000820
146. Menthol Racemate [mi]
147. Spectrum1503134
148. Menthol,3r,4s)-(-)-
149. Spbio_000869
150. Gtpl2430
151. Npo-11
152. Dtxsid1020805
153. Dtxsid1022180
154. (-)-menthol, Usp, 97%
155. Hms502i22
156. Kbio1_000820
157. Kbio2_000785
158. Kbio2_003353
159. Kbio2_005921
160. Kbio3_002562
161. Noolisfmxdjskh-kxucptdwsa-
162. (-)-menthol, Analytical Standard
163. Ninds_000820
164. Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r,3r,4s)-
165. Hms1922g13
166. Hms2092l14
167. Hms3885j18
168. Levomenthol [ep Monograph]
169. Pharmakon1600-01503134
170. Cyclohexanol, 2-isopropyl-5-methyl
171. Nsc62788
172. Zinc1482164
173. L-menthol, >=99%, Fcc, Fg
174. Tox21_111620
175. Tox21_201823
176. Tox21_201919
177. Tox21_202608
178. Tox21_302999
179. Tox21_303028
180. Wln: L6tj Ay1&1 Bq D1
181. Bdbm50318482
182. Ccg-40300
183. Cyclohexanol, 2-isopropyl-5-methyl-
184. Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1alpha,2beta,5alpha)-
185. Nsc758395
186. S4714
187. Akos016842647
188. (1r, 2s, 5r-)-(-)-menthol
189. Bs-3863
190. Db00825
191. Lmpr0102090001
192. Nsc-758395
193. Sdccgmls-0066659.p001
194. (-)-trans-p-methan-cis-3-ol
195. 1-iso Propyl-4-methyl Cyclohexan-2-ol
196. Idi1_000820
197. Wln: L6tj Ay1&1 Dq D1 -l
198. Ncgc00164247-01
199. Ncgc00164247-02
200. Ncgc00164247-03
201. Ncgc00256525-01
202. Ncgc00256561-01
203. Ncgc00259372-01
204. Ncgc00259468-01
205. Ncgc00260156-01
206. D-(-)-phenylglycine Dane Potassium Salt
207. Fema No. 2665, (-)-
208. Smr001306785
209. L-menthol, Natural, >=99%, Fcc, Fg
210. Sbi-0051777.p002
211. N1950
212. S5868
213. Fema No. 2665, (+/-)-
214. Menthol (racemic) 100 Microg/ml In Methanol
215. (+/-)-(1r*,3r*,4s*)-menthol
216. (1r,2s,5r)-(-)-menthol, Synthetic Pellets
217. C00400
218. Cyclohexanol, (1.alpha.,2.beta.,5.alpha.)-
219. D00064
220. D70313
221. (1r,2r,5s)-2-isopropyl-5-methyl-cyclohexanol
222. Ab00052320_02
223. L-menthol
224. Levomenthol
225. Menthomenthol
226. Menthacamphor
227. (1r,2s,5r)-(-)-menthol, >=99%, Sublimed
228. A843308
229. Q407418
230. Q-201316
231. Sr-05000001936-1
232. Sr-05000001936-2
233. (-)-menthol, Primary Pharmaceutical Reference Standard
234. (1r,2s,5r)-(-)-menthol, Reagentplus(r), 99%
235. 2-isopropyl-5-methylcyclohexanol-, (1r,2s,5r)- #
236. Cyclohexanol, [1r-(1.alpha.,2.beta.,5.alpha.)]-
237. (1r,2s,5r)-5-methyl-2-propan-2-yl-cyclohexan-1-ol
238. Z1698549655
239. (1r,2s,5r)-(-)-menthol, Vetec(tm) Reagent Grade, 98%
240. 6c6a4a8c-a054-468c-a1f0-f29e39838cf2
241. (1r, 2s, 5r)-5-methyl-2-(1-methylethyl)cyclohexyl Alcohol
242. Menthol, United States Pharmacopeia (usp) Reference Standard
243. (1r,2s,5r)-rel-5-methyl-2-(1-methylethyl)cyclohexanol
244. L-menthol, Pharmaceutical Secondary Standard; Certified Reference Material
245. (-)-menthol, Puriss., Meets Analytical Specification Of Ph. Eur., Bp, Usp, 98.0-102.0%
246. (1r-(1-.alpha.,2-.beta.,5-.alpha.))-5-methyl-2-(1-methylethyl)cyclohexanol
247. 114376-98-6
Molecular Weight | 156.26 g/mol |
---|---|
Molecular Formula | C10H20O |
XLogP3 | 3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 1 |
Exact Mass | 156.151415257 g/mol |
Monoisotopic Mass | 156.151415257 g/mol |
Topological Polar Surface Area | 20.2 Ų |
Heavy Atom Count | 11 |
Formal Charge | 0 |
Complexity | 120 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
INHALERS CONTAINING MENTHOL COMPRESSED INTO BLOCKS OR CONES ARE COMMONLY USED FOR THE RELIEF OF NASAL CONGESTION, HEADACHE, AND NEURALGIA. IT IS NOW RARELY ADMINISTERED INTERNALLY. /MENTHOL/
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 722
TOPICAL ANTIPRURITIC; MEDICATION (VET): HAS BEEN USED AS A MILD LOCAL ANESTHETIC, ANTISEPTIC & INTERNALLY AS A CARMINATIVE & GASTRIC SEDATIVE /MENTHOL/
The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 757
IN LIQUEURS, CONFECTIONERY, PERFUMERY, CIGARETTES, COUGH DROPS, AND NASAL INHALERS /MENTHOL/
The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 757
"COOLING" EFFECT OF L-MENTHOL WAS FOUND...TO BE SUPERIOR TO THAT PRODUCED BY OTHER ISOMERS; ODOR AND TASTE, TOO OF L-MENTHOL WERE SUPERIOR, WITH SOME OF THE ISOMERS PRODUCING SHARP, IRRITATING AND DISAGREEABLE PERCEPTIONS.
Osol, A., and R. Pratt. (eds.). The United States Dispensatory. 27th ed. Philadelphia: J.B. Lippincott, 1973., p. 697
Used to treat occasional minor irritation, pain, sore mouth, and sore throat as well as cough associated with a cold or inhaled irritants.
Menthol is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. Menthol induces a cooling sensation on the skin upon inhalation, oral ingestion, or topical application by stimulating the cold-sensitive receptors expressed on the skin, without actually causing a drop in the skin temperature.
...THE PERCENTAGE OF A DOSE OF L-MENTHOL THAT IS EXCRETED COMBINED WITH GLUCURONIC ACID IN THE RABBIT DEPENDS ON THE MAGNITUDE OF THE DOSE; THE LARGER THE DOSE, THE LESS IS THE CONJUGATION.
Opdyke, D.L.J. (ed.). Monographs on Fragrance Raw Materials. New York: Pergamon Press, 1979., p. 519
L-MENTHOL CONJUGATES READILY IN RABBIT FORMING L-MENTHYL-BETA-D-GLUCURONIDE. ABOUT HALF OF THE L-MENTHOL FED TO RABBITS IS EXCRETED COMBINED WITH GLUCURONIC ACID; THE FATE OF OTHER HALF IS NOT KNOWN, BUT IT IS POSSIBLE THAT RING FISSION OCCURS WITH CONSIDERABLE DEGRADATION OF THE MENTHOL MOLECULE.
Opdyke, D.L.J. (ed.). Monographs on Fragrance Raw Materials. New York: Pergamon Press, 1979., p. 519
IN DOGS, MUCH OXIDATION OF MENTHOL TAKES PLACE AND ONLY ABOUT 5% OF THE DOSE CAN BE RECOVERED IN URINE AS THE GLUCURONIDE. /MENTHOL/
Opdyke, D.L.J. (ed.). Monographs on Fragrance Raw Materials. New York: Pergamon Press, 1979., p. 519
L-MENTHOL WAS RAPIDLY BUT INCOMPLETELY GLUCURONIDATED. THE OUTPUT OF L-MENTHOL GLUCURONIDE WAS INCR IN ALL BUT 1 SUBJECT PRETREATED WITH CIMETIDINE (1 G/DAY FOR 1 WK), AN INHIBITOR OF OXIDATIVE DRUG METABOLISM, & IN ALL SUBJECTS PRETREATED WITH A DRUG-METABOLIZING ENZYME INDUCER, PHENOBARBITONE (60 MG NIGHTLY FOR 10 DAYS).
BELL GD ET AL; BR J CLIN PHARMACOL 12 (2): 274 (1981)
Corynebacterium sp. strain RWM1 grew with (-)-menthol, (-)-menthone and other acyclic monoterpenes as sole carbon sources. Growth on menthol was very slow, with a doubling time of more than 24 h, and was not rapid with (-)-menthone (doubling time 12 h). Concentrations of either carbon source greater than 0.025% inhibited growth. (-)-Menthone-grown cultures transiently accumulated 3,7-dimethyl-6-hydroxyoctanoate during growth, and (-)-menthol-grown cells oxidized (-)-menthol, (-)-menthone, 3,7-dimethyl-6-octanolide and 3,7-dimethyl-6-hydroxyoctanoate. Although neither a menthol oxidase nor a menthol dehydrogenase could be detected in extracts of (-)-menthol- or (-)-menthone-grown cells, an induced NADPH-linked monooxygenase with activity towards (-)-menthone was readily detected. With crude cell extracts, only 3,7-dimethyl-6-hydroxyoctanoate was detected as the reaction product. When the (-)-menthone monooxygenase was separated from an induced 3,7-dimethyl-6-octanolide hydrolase by chromatography on hydroxyapatite, the lactone 3,7-dimethyl-6-octanolide was shown to be the product of oxygenation.
Williams DR, PW Trudgill; Microbiology (Reading) 140 (3): 611-6 (1994)
(-)-Menthol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxyoxane-2-carboxylic acid and p-Menthane-3,-8-diol.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Menthol primarily activates the cold-sensitive TRPM8 receptors in the skin. Menthol, after topical application, causes a feeling of coolness due to stimulation of 'cold' receptors by inhibiting Ca++ currents of neuronal membranes. It may also yield analgesic properties via kappa-opioid receptor agonism.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28691
Submission : 2014-09-29
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37683
Submission : 2022-11-11
Status : Active
Type : IV
Date of Issue : 2023-04-18
Valid Till : 2026-04-18
Written Confirmation Number : WC-0554
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35643
Submission : 2021-02-15
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36666
Submission : 2022-01-12
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23408
Submission : 2009-12-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15452
Submission : 2001-05-11
Status : Active
Type : II
Registration Number : 217MF10801
Registrant's Address : Hyogo Prefecture Nishinomiya City Nishinomiyahama 4-7-18
Initial Date of Registration : 2005-11-01
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30689
Submission : 2016-06-23
Status : Active
Type : IV
Registration Number : 217MF11171
Registrant's Address : 5-37-1 Kamata, Ota-ku, Tokyo
Initial Date of Registration : 2005-12-12
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35376
Submission : 2021-01-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22154
Submission : 2008-11-03
Status : Active
Type : II
Certificate Number : R1-CEP 2004-100 - Rev 03
Issue Date : 2020-04-21
Type : Chemical
Substance Number : 619
Status : Valid
Registration Number : 218MF10705
Registrant's Address : Muehlenfeldstrasse 1 D-37 603 Holzminden Germany
Initial Date of Registration : 2006-08-11
Latest Date of Registration : --
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-08-26
Pay. Date : 2020-06-08
DMF Number : 26711
Submission : 2012-12-03
Status : Active
Type : II
Certificate Number : R1-CEP 2012-390 - Rev 01
Issue Date : 2021-06-16
Type : Chemical
Substance Number : 619
Status : Valid
NDC Package Code : 48041-0001
Start Marketing Date : 2014-07-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Co-Processed Excipients
Excipient Details : DiCOM-DC S604 is used as a DC co-processed excipient with a combination of various polymers that act as fillers and binders in tablets and capsules.
Pharmacopoeia Ref : In-house
Technical Specs : Polyvinyl Pyrrolidone 97% & 93%
Ingredient(s) : Calcium Carbonate Excipient
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Brand Name : Innogel 9000/9500
Application : Fillers, Diluents & Binders
Excipient Details : Innogel 9000/9500 (Pregelatinized Starch) is used as filler, binder, disintegrant, and superdisintegrant in tablets and capsules.
Pharmacopoeia Ref : IP/BP/EP/USP-NF
Technical Specs : NA
Ingredient(s) : Corn Starch, Pregelatinized
Dosage Form : Capsule
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : Sallyso (Croscarmellose Sodium) is used as a disintegrating agent in tablets, capsules & granules for enhancing API dissolution and bioavailability.
Pharmacopoeia Ref : IP/BP/EP/USP-NF
Technical Specs : Sallyso 0.5 to 3.0%
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Softgels
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Syrup
Grade : Oral
Dosage Form : Tablet
Grade : Not Available
Application : Controlled & Modified Release
Excipient Details : Solubilization, dispersion, crystallization inhibition, instant release matrices & spray drying
Dosage Form : Tablet
Grade : Not Available
Application : Solubilizers
Excipient Details : Solubilization, dispersion, crystallization inhibition, instant release matrices & spray drying
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Disintegrants & Superdisintegrants
Excipient Details : Maximum disintegration
Pharmacopoeia Ref : Ph. Eur., USP, JP: Crospovidon...
Technical Specs : Not Available
Ingredient(s) : Polyvinylpyrrolidone Crosslinked
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : For non-erodible matrices using direct compression, Controlled release matrix. Matrix former in transdermal patches and topical films.
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP-JPE: 80 %...
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Film Formers & Plasticizers
Excipient Details : Liquid plasticizer with high ADI, hydrophilic solvent & humectant in emulsions, skin penetration enhancer in topical formulaitons.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Propylene Glycol
Dosage Form : Cream / Lotion / Ointment
Grade : Not Available
Application : Topical
Excipient Details : Structure-building consistency factor for semi-solids. Viscosity regulator.
Pharmacopoeia Ref : Ph. Eur., USP-NF: Cetyl alcoho...
Technical Specs : Not Available
Ingredient(s) : Cetyl Alcohol
Dosage Form : Softgel Capsule
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : Structure-building consistency factor with dry feel, forms crystalline barrier on skin
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP: Stearic ...
Technical Specs : Not Available
Ingredient(s) : Stearic Acid
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : Lipophilic lubricant, for sensitive acidic APIs, Structure-building consistency factor for semi-solids, Viscosity regulator.
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP: Stearyl ...
Technical Specs : Not Available
Ingredient(s) : Stearyl Alcohol
Dosage Form : Orodispersible Tablet
Grade : Not Available
Application : Chewable & Orodispersible Aids
Excipient Details : Ludiflash is a ready-to-use orally disintegrating tablet (ODT) solution with superior mouthfeel.
Pharmacopoeia Ref : Ph. Eur., USP, JP: 90 % mannit...
Technical Specs : Not Available
Ingredient(s) : Crospovidone
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : Ready-to-use direct compression solution for tablets.
Pharmacopoeia Ref : Ph.Eur., USP/NF and JP
Technical Specs : Not Available
Ingredient(s) : Crospovidone
Dosage Form : Tablet
Grade : Oral, Parenteral
Application : Controlled & Modified Release
Excipient Details : PLGA-PEG is used in the synthesis of targeted nanoparticles which are used for differential delivery and controlled release of drugs.
Pharmacopoeia Ref : NA
Technical Specs : Nano-particles, ultrapure, low-monomer & powder grades.
Ingredient(s) : Poly-DL-Lactic-co-Glycolic Acid
Dosage Form : Tablet
Grade : Oral, Parenteral
Application : Controlled & Modified Release
Excipient Details : PLLA-PEG used in the synthesis of targeted nanoparticles which are used for differential delivery and controlled release of drugs.
Pharmacopoeia Ref : NA
Technical Specs : Nano-particles, ultrapure, low-monomer & powder grades
Ingredient(s) : Poly L Lactide
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A CAS-2216-51-5 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CAS-2216-51-5, including repackagers and relabelers. The FDA regulates CAS-2216-51-5 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CAS-2216-51-5 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CAS-2216-51-5 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CAS-2216-51-5 supplier is an individual or a company that provides CAS-2216-51-5 active pharmaceutical ingredient (API) or CAS-2216-51-5 finished formulations upon request. The CAS-2216-51-5 suppliers may include CAS-2216-51-5 API manufacturers, exporters, distributors and traders.
click here to find a list of CAS-2216-51-5 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CAS-2216-51-5 DMF (Drug Master File) is a document detailing the whole manufacturing process of CAS-2216-51-5 active pharmaceutical ingredient (API) in detail. Different forms of CAS-2216-51-5 DMFs exist exist since differing nations have different regulations, such as CAS-2216-51-5 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CAS-2216-51-5 DMF submitted to regulatory agencies in the US is known as a USDMF. CAS-2216-51-5 USDMF includes data on CAS-2216-51-5's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CAS-2216-51-5 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CAS-2216-51-5 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CAS-2216-51-5 Drug Master File in Japan (CAS-2216-51-5 JDMF) empowers CAS-2216-51-5 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CAS-2216-51-5 JDMF during the approval evaluation for pharmaceutical products. At the time of CAS-2216-51-5 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CAS-2216-51-5 suppliers with JDMF on PharmaCompass.
A CAS-2216-51-5 CEP of the European Pharmacopoeia monograph is often referred to as a CAS-2216-51-5 Certificate of Suitability (COS). The purpose of a CAS-2216-51-5 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CAS-2216-51-5 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CAS-2216-51-5 to their clients by showing that a CAS-2216-51-5 CEP has been issued for it. The manufacturer submits a CAS-2216-51-5 CEP (COS) as part of the market authorization procedure, and it takes on the role of a CAS-2216-51-5 CEP holder for the record. Additionally, the data presented in the CAS-2216-51-5 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CAS-2216-51-5 DMF.
A CAS-2216-51-5 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CAS-2216-51-5 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CAS-2216-51-5 suppliers with CEP (COS) on PharmaCompass.
A CAS-2216-51-5 written confirmation (CAS-2216-51-5 WC) is an official document issued by a regulatory agency to a CAS-2216-51-5 manufacturer, verifying that the manufacturing facility of a CAS-2216-51-5 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CAS-2216-51-5 APIs or CAS-2216-51-5 finished pharmaceutical products to another nation, regulatory agencies frequently require a CAS-2216-51-5 WC (written confirmation) as part of the regulatory process.
click here to find a list of CAS-2216-51-5 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CAS-2216-51-5 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CAS-2216-51-5 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CAS-2216-51-5 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CAS-2216-51-5 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CAS-2216-51-5 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CAS-2216-51-5 suppliers with NDC on PharmaCompass.
CAS-2216-51-5 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CAS-2216-51-5 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CAS-2216-51-5 GMP manufacturer or CAS-2216-51-5 GMP API supplier for your needs.
A CAS-2216-51-5 CoA (Certificate of Analysis) is a formal document that attests to CAS-2216-51-5's compliance with CAS-2216-51-5 specifications and serves as a tool for batch-level quality control.
CAS-2216-51-5 CoA mostly includes findings from lab analyses of a specific batch. For each CAS-2216-51-5 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CAS-2216-51-5 may be tested according to a variety of international standards, such as European Pharmacopoeia (CAS-2216-51-5 EP), CAS-2216-51-5 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CAS-2216-51-5 USP).
LOOKING FOR A SUPPLIER?